cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Exscientia Plc
9 own
4 watching
Current Price
$5.2
$0.07
(1.36%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,012.52M
52-Week High
52-Week High
9.12000
52-Week Low
52-Week Low
3.86000
Average Volume
Average Volume
0.94M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,012.52M
icon52-Week High9.12000
icon52-Week Low3.86000
iconAverage Volume0.94M
iconDividend Yield--
iconP/E Ratio--
What does the Exscientia Plc do?
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Read More
News & Events about Exscientia Plc.
Business Wire
1 year ago
Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL. Were excited to further validate Exscientias end-to-end approach of integrating outstanding science with...
PR Newswire
1 year ago
Thinking about buying stock in Newmark Group, Exscientia, Pardes Biosciences, Creative Medical Technology, or Somalogic? Thinking about buying stock in Newmark Group, Exscientia, Pardes Biosciences, Creative Medical Technology, or Somalogic? PR Newswire NEW YORK, April 12, 2023 NEW YORK, April 12...
Business Wire
1 year ago
Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States. The compound is in development for immunology & inflammation...
Business Wire
1 year ago
Exscientia plc (Nasdaq: EXAI) today announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its first European country. IGNITE-AI is a Phase 1/2 trial studying EXS-21546 ('546), Exscientias A2A receptor antagonist in combination with anti-PD-1 therapy in...
Frequently Asked Questions
Frequently Asked Questions
What is Exscientia Plc share price today?
plus_minus_icon
Can Indians buy Exscientia Plc shares?
plus_minus_icon
How can I buy Exscientia Plc shares from India?
plus_minus_icon
Can Fractional shares of Exscientia Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Exscientia Plc stocks?
plus_minus_icon
What is today’s traded volume of Exscientia Plc?
plus_minus_icon
What is today’s market capitalisation of Exscientia Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Exscientia Plc?
plus_minus_icon
What percentage is Exscientia Plc down from its 52-Week High?
plus_minus_icon
What percentage is Exscientia Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.2
$0.07
(1.36%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00